Improving outcomes of patients with venovenous extracorporeal membrane oxygenation

R) may facilitate ultra-protective ventilation but lacks a proven mortality benefit. Therefore, its use is currently not recommended outside the setting of well-designed clinical trials. Weaning from ECMO should be structured and guided by physiological readiness while maintaining lung-protective ventilation. Optimal outcomes are achieved in high-expertise, multidisciplinary centres, with ongoing research needed to refine patient selection, ventilation strategies, and complication management. Overall, VV ECMO remains an essential tool in the management of severe respiratory failure, requiring careful balancing of risks, resources, and individualized clinical decision-making.